Corcept’s ALS drug demonstrates two-year benefit despite primary endpoint miss
Corcept Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has shown two-year survival benefit above placebo, despite the trial having failed to …
Post
-
-
The cost of inefficiencies in clinical trials
Clinical trials are expensive, time-sensitive, and closely monitored, with sponsors and contract research organisations (CROs) under pressure to run studies …
-
How Saudi Arabia is developing as a Middle East hub for clinical trials
Saudi Arabia is primed to emerge as the Middle East’s key hub for clinical trials, driven by both sustained state …
-
Bambusa completes enrolment in BBT001 Phase Ib/IIa trial for atopic dermatitis
Bambusa Therapeutics has completed patient enrolment in its Phase Ib/IIa trial evaluating BBT001 as a treatment for moderate-to-severe atopic dermatitis …
-
Merck KGaA doses first patient in Phase III programme of enpatoran
Merck KGaA (Merck) has dosed the first patient in its Phase III clinical programme, ELOWEN-1 and ELOWEN-2, evaluating the oral …
-
Merck KGaA doses first patient in Phase III programme of enpatoran
Merck KGaA (Merck) has dosed the first patient in its Phase III clinical programme, ELOWEN-1 and ELOWEN-2, evaluating the oral …
-
Wave of AI and data science tools set to transform clinical trials
The clinical trial sector is experiencing a rapid influx of artificial intelligence (AI) and data science tools, as companies seek …
-
Patient death puts Newron’s late-stage schizophrenia trial on ice
US regulators have pressed pause on enrolment to Newron Pharmaceuticals’ Phase III trial on lead schizophrenia candidate, evenamide, after a …
-
Pfizer hoping for earlier Elrexfio use in RRMM after Phase III trial
Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug showed …
-
EU’s Joint Clinical Assessment system still finding its footing
In April, Ipsen’s Ojemda (tovorafenib) secured European Commission (EC) approval for the treatment of relapsed or refractory paediatric low-grade glioma. …
-
How eSource adoption is saving time and costs in clinical research
Clinical trial sites and sponsors are turning to eSource to ease pressures over costs and unlock efficiencies, with a recent …
-
First patient dosed in Newleos’ Phase Ib trial of NTX-2001
Newleos Therapeutics has dosed the first participant in its Phase Ib clinical study evaluating NTX-2001, a partial agonist of trace …
-
Low patient accrual continues to hinder male infertility trials
Male infertility can be caused by numerous lifestyle factors, including poor lifestyle, genetic factors, or specific drug treatments such as …
-
Precision begins patient enrolment for FUNCTION-DMD trial
Precision BioSciences has activated Arkansas Children’s Hospital as the first site and initiated patient enrolment for its Phase I/II FUNCTION-DMD …
-
Boehringer’s weight loss jab as good as Wegovy but not Zepbound
Boehringer Ingelheim’s (BI’s) weight loss jab has shown similar efficacy to Wegovy (semaglutide) but a strength inferior to Zebound (tirzepatide). The …
